Vimian Group (VIMIAN) Q4 2025 earnings summary

Executive summary

• Achieved 13% revenue growth and 6% organic growth for 2025, with broad-based performance across all segments and strong operational cash flow of EUR 105.7 million.

• Adjusted EBITDA/EBITA grew 11% to EUR 105.3 million, with margin at 24.8%.

• Completed transition to Nasdaq Main Market, now classified as a large cap.

• Five acquisitions in 2025, including I-Vet in Italy, expanding portfolio and geographic reach.

• CEO transition and key management changes occurred during and after the quarter.

Financial highlights

• Q4 2025 revenue grew 4% to EUR 109 million, with 6% organic growth and 6% adjusted EBITDA/EBITA growth; margin improved 60 bps to 24.0%.

• Q4 operating profit (EBIT) rose 54% to EUR 19.2 million; Q4 profit EUR 12.2 million; EPS EUR 0.02.

• Cash flow from operating activities in Q4 was EUR 55.7 million, including EUR 28.7 million from U.S. indemnification.

• Net debt at year-end: EUR 245.4 million; leverage ratio 2.0x; cash and cash equivalents at EUR 55.0 million.

• No dividend proposed for 2025.

Outlook and guidance

• Expecting continued good growth in 2026, supported by positive market momentum and robust M&A pipeline.

• Specialty Pharma and cross-selling initiatives expected to drive double-digit organic growth.

• MedTech segment anticipated to return to year-over-year growth later in spring 2026, with full recovery dependent on market conditions.

• Veterinary Services to maintain high investment pace to capture growth opportunities.

• Focus remains on organic and acquisition-driven growth, with continued investments in new products and markets.